Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K current report with the SEC on March 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Supply Agreement with Letop (March 3, 2026): ANP sources chemical intermediates; 5-year term, no minimum purchase obligation, payments in Chinese yuan.
Amphastar Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Supply Agreement with Letop (March 3, 2026): ANP sources chemical intermediates; 5-year term, no minimum purchase obligation, payments in Chinese yuan
- Related party risk: Letop majority-owned by Henry Zhang, son of CEO Dr. Jack Zhang and COO Dr. Mary Luo; Audit Committee approval required and obtained
- Contract Research Amendment shifts Hanxin's cell bank work from AMP-107 to AMP-105, adding ~$0.6M to total contract cost
- Dual related-party concentration: Hanxin also majority-owned by Zhang/Luo family, with Henry Zhang serving as general manager and board chairman
- Both transactions deemed non-material to financials by company, but related-party ties to top executives warrant ongoing governance scrutiny
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amphastar Pharmaceuticals, Inc. 8-K filings
Get the next AMPH 8-K as it lands
Follow AMPH for push alerts, or ask the research agent what this filing means.